About BTI


Boston Therapeutics, Inc. (OTCQB: BTHE) is a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes.

The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules:

BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. BTI-320 inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.

IPOXYN™ is a glyco-protein based therapeutic agent using proprietary processes and patented technology. IPOXYN™ is an anti-necrosis drug that consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.

OXYFEX™ can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events.